Anthera Pharma (ANTH) PT Lowered to $1.75 at Jefferies Following 2Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pre-Open Stock Movers 08/10: (HDSN) (GLPG) (PRGO) Higher; (BW) (QTM) (CBI) Lower (more...)
August 10, 2017 9:27 AM EDTToday's Pre-Open Movers
Babcock & Wilcox (NYSE: BW) 29.2% LOWER; reported Q2 EPS of ($2.56), which may not compare to the analyst estimate of $0.06. Revenue for the quarter came in at $349.8 million versus the consensus estimate of $434.34 million.
Quantum Corp. (NYSE: QTM) 22.3% LOWER; reported Q1 EPS of $0.04, $0.01 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $116.9 million versus the consensus estimate of $119.41 million. Quantum Corp. sees FY2018 revenue of $515-525 million, versus the consensus of $528.43... More
After-Hours Stock Movers 08/09: (HDSN) (ASYS) (LYV) Higher; (BW) (QTM) (CBI) Lower (more...)
August 9, 2017 6:01 PM EDTToday's After-Hours Movers
Babcock & Wilcox (NYSE: BW) 29.2% LOWER; reported Q2 EPS of ($2.56), which may not compare to the analyst estimate of $0.06. Revenue for the quarter came in at $349.8 million versus the consensus estimate of $434.34 million.
Quantum Corp. (NYSE: QTM) 22.3% LOWER; reported Q1 EPS of $0.04, $0.01 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $116.9 million versus the consensus estimate of $119.41 million. Quantum Corp. sees FY2018 revenue of $515-525 million, versus the consensus of $528.43 million.
Hudson... More
Anthera Pharma (ANTH) Confirms FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy
August 9, 2017 4:01 PM EDTAnthera Pharmaceuticals (Nasdaq: ANTH) today announced that blisibimod has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Immunoglobulin A nephropathy (IgAN). Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including IgAN, systemic lupus erythematosus, and others.
We are pleased by the FDAs decision to designate blisibimod with orphan drug designation, said Craig Thompson, Chief Executive Officer of... More
Anthera Pharma's (ANTH) Blisibimod Receives FDA Orphan Drug Status
August 9, 2017 6:25 AM EDTAnthera Pharma' (NASDAQ: ANTH) Blisibimod received FDA orphan drug status for treatment of patients with immunoglobulin A... More
